Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bioequivalence Data: Statistical Interpretation

Bioequivalence Data: Statistical Interpretation

Body:The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...

Analysis of Population Pharmacokinetic Data

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...

Model Approaches for Pharmacokinetic Data: Compartment Models

Model Approaches for Pharmacokinetic Data: Compartment Models

Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...

Noncompartmental Analysis: Miscellaneous Pharmacokinetic Parameters

Noncompartmental Analysis: Miscellaneous Pharmacokinetic Parameters

The noncompartmental approach is a widely used method in pharmacokinetics to assess drugs' behaviors in the body. It considers several factors, including clearance, bioavailability, and total volume of distribution.
One key aspect of the noncompartmental approach is determining a drug's total clearance. This can be done by dividing the drug dose by the area under the concentration-time curve from zero to infinity. The area under the concentration-time curve represents the drug's...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Lung infection of avian pathogenic Escherichia coli co-upregulates the expression of cSP-A and cLL in chickens.

Research in veterinary science·2022

Same author

Nickel/nitrogen-doped carbon nanocomposites: Synthesis and electrochemical sensor for determination of p-nitrophenol in local environment.

Environmental research·2022

Same author

Ca<sup>2+</sup> homeostasis maintained by TMCO1 underlies corpus callosum development via ERK signaling.

Cell death & disease·2022

Same author

Potato (Solanum tuberosum L.) non-specific lipid transfer protein StLTP6 promotes viral infection by inhibiting virus-induced RNA silencing.

Planta·2022

Same author

Prevalence and associated factors of frailty among community dwelling older adults in Northwest China: a cross-sectional study.

BMJ open·2022

Same author

Identifying the Subtypes of Major Depressive Disorder Based on Somatic Symptoms: A Longitudinal Study Using Latent Profile Analysis.

Frontiers in psychiatry·2022

Search research articles

Related Experiment Videos

Discordancy Partitioning for Validating Potentially Inconsistent Pharmacogenomic Studies.

J Sunil Rao^1,2, Hongmei Liu³

¹Division of Biostatistics, Department of Public Health Sciences, University of Miami, Florida, USA. jrao@miami.edu.

Scientific Reports

|November 11, 2017

Summary

This summary is machine-generated.

This study introduces a novel data partitioning strategy to address challenges in validating cancer drug sensitivity models. The method improves the accuracy of predictions and identifies reproducible gene-drug interaction signatures across datasets like GDSC and CCLE.

Related Experiment Videos

Area of Science:

Genomics
Cancer Research
Pharmacogenomics

Background:

The Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Cell Line Encyclopedia (CCLE) are key resources for identifying cancer therapeutic biomarkers.
Model validation across these large-scale datasets is challenging due to inconsistencies in drug response data, despite similar genomic profiling.

Purpose of the Study:

To present a novel partitioning strategy for robust model validation and biomarker discovery using cancer genomics and drug sensitivity data.
To address the lack of concordance between datasets like GDSC and CCLE for reliable therapeutic biomarker mining.

Main Methods:

A data partitioning strategy based on a data sharing concept was developed.
This approach directly accounts for potential data non-concordance between different cancer datasets.
The strategy was applied to re-analyze the GDSC and CCLE datasets.

Main Results:

The proposed partitioning strategy enables accurate test set predictions.
Reproducible novel gene-drug interaction signatures were extracted.
The method demonstrated improved model validation across disparate datasets.

Conclusions:

The developed partitioning strategy offers a robust solution for validating cancer drug sensitivity models.
It facilitates the reliable identification of therapeutic biomarkers and gene-drug interactions.
This approach enhances the utility of large-scale cancer datasets like GDSC and CCLE for precision medicine.